able in vivo biomarkers to monitor disease severity and reflect the underlying dopaminergic degeneration is important for future disease-modifying therapy in PD.
A noninvasive neuroimaging technique with radiotracers targeting the dopaminergic system from both positron emission tomography (PET) and single-photon emission computed tomography is an ideal method to monitor disease severity and investigate neural degeneration in PD. [4] [5] [6] [7] [8] [9] To serve as an objective biomarker for disease progression in PD, study of the correlation of imaging patterns and quantitation for an imaging tracer to clinical measures of disease severity is important. 10 Previous studies have been conducted on the correlation of the striatal uptake of [
18 F]fluorodopa PET, for measuring aromatic amino acid decarboxylase activity, to disease severity. 11, 12 The correlations of dopamine transporter loss using iodine I 123-labeled 2β-carbomethoxy-3β-(4-iodophenyl) tropane and 99m Tc-labeled tropane derivative single-photon emission computed tomography with PD stage and severity have been reported. 4, 6 Nevertheless, both aromatic amino acid decarboxylase activity and dopamine transporter density are regulated by disease and antiparkinsonian medications, [13] [14] [15] [16] [17] which greatly limit their applications in measuring the dopaminergic degeneration precisely. 14, 18 Vesicular monoamine transporter type 2 (VMAT2) is the protein responsible for pumping monoamines from cytosol into synaptic vesicles. Vesicular monoamine transporter type 2 imaging using PET tracer 11 C-dihydrotetrabenazine ( 11 C-DTBZ) has been proven to be an objective marker of nigrostriatal terminal integrity. 19 Although VMAT2 availability may be sensitive to vesicular dopamine levels, 20 previous studies have suggested there is no long-term regulation effect on the VMAT2 binding sites by dopaminergic drugs for PD. 21-24 Using 11 C-DTBZ PET, an age-dependent VMAT2 decline in normal individuals was observed along with the significant correlation of striatal binding reduction to disease duration in PD. 25 The asymmetry of VMAT2 binding was also highly correlated with clinical asymmetry. Another study reported the effectiveness of 11 C-DTBZ imaging for evaluating the evolution of dopamine neuron loss in a nonhuman primate model of PD at different stages. 
Image Analysis
All image data were processed and analyzed using PMOD image analysis software (version 3.3, PMOD Technologies Ltd). The 3-D visualization of the VMAT2 distribution were processed and displayed as overlaid with corresponding nigrostriatal volumes of interest (VOIs) using the Avizo software (version 7, VSG Co). Each PET image was coregistered to the corresponding MRI scan, and the individual MRI scan was spatially normalized to the Montreal Neurological Institute MRI template. 34 The spatial normalization parameters were then applied to PET images to form a final, spatially normalized PET image in the Montreal Neurological Institute domain. Volumes of interest of bilateral caudate nuclei, anterior/ posterior putamen (APu/PPu), nucleus accumbens (NAc), SN, raphe, amygdala, hippocampus, locus coeruleus (LC), and occipital cortex were defined on the MRI template. The occipital cortex was applied as the reference region for computing specific uptake ratio (SUR) by (target uptake − reference uptake) / reference uptake. 7, 35 In the PD group, the contralateral VOIs were defined as the opposite brain regions to the predominantly affected limbs and were evaluated separately from the ipsilateral VOIs. In the HC group, the mean values from bilateral regional SURs were calculated for comparison.
Statistical Analysis
The regional SUR of the 18 F-DTBZ PET images and clinical data were statistically compared using the nonparametric KruskalWallis test with post hoc test (Dunn multiple comparison test) for group comparison among HC individuals and patients with PD of different stages. The correlations between quantitative parameters of PD images and clinical characteristics (ie, disease severity, UPDRS score, and disease duration) were examined for each VOI using exponential regression analysis. P = .05 was selected as the threshold of statistical significance in each test. Table 1 shows the demographic data of all participants. In the mild PD group, the parameters, including disease duration, mH-Y stage, UPDRS total scores, UPDRS motor scores (UPDRS III), PI/GD, and akinesia scores, were significantly lower than those of the moderate and advanced PD groups (P < .001). Figure 1 illustrates the average 18 F-DTBZ uptakes in 2-D and 3-D images from HC individuals and patients with PD. Images in HC individuals revealed a symmetric distribution pattern with the highest uptake in striatal regions and moderate uptake in the SN, raphe, hippocampus, amygdala, and hypothalamus ( Figure 1A and B). The caudate nucleus and putamen could be easily separated by visual assessment in 2-D images. The 3-D image of HC individuals represented an integral and visible functional anatomy of dopaminergic, serotoninergic, and norepinephrinergic innervations.
Results
The VMAT2 availability in nigrostriatal regions was obviously decreased with the progression of clinical severity in PD. Figure 1C and D demonstrate a typical pattern of selective dopaminergic degeneration in mild PD as an obviously asymmetric activity decline in nigrostriatum with the greatest loss in contralateral PPu. In moderate PD ( Figure 1E and F), the uptake reduction in the caudate, APu, and SN was more obvious. At this stage, the asymmetry of striatal uptake became less discernible. The characteristic of VMAT2 distribution in the advanced PD group ( Figure 1G and H) was similar to that of moderate PD but with a more severe uptake decline in all regions. The correlation between dopamine neuron loss and disease progression from HC individuals to patients with advanced PD could be better visualized in 3-D views. The decline of VMAT2 began from the contralateral PPu, followed by the ipsilateral PPu, and then extended to the APu and caudate. In advanced PD, the striatal VMAT2 activity could be observed only in the NAc and head of the caudate, whereas the activity was relatively preserved in the extrastriatal regions including the hippocampus, amygdala, raphe, and LC (Video). Table 2 shows the regional 18 F-DTBZ SUR values for the HC individuals and patients with PD. As demonstrated, regional SURs of the striatum and SN in both the moderate and advanced PD groups were significantly lower than those in the HC group. Only the SURs of contralateral APu and PPu in mild PD were different from those of HC individuals. Specific uptake ratios of all striatal regions in moderate and advanced PD revealed a significant difference (P < .05) from those with mild PD. Nevertheless, there were no significant SUR differences in the raphe, hippocampus, and amygdala among HC individuals and patients with PD for all stages.
Percentage declines of regional uptake in the bilateral nigrostriatal regions for PD at different stages compared with HC individuals are also displayed in Table 2 . In the nigrostriatal pathway, VMAT2 activities were reduced markedly in the PPu, followed by the APu and caudate, but less affected in the SN. Activity reduction in the PPu was greater than 60% for all stages of PD. There was no sex difference for regional SURs except in the contralateral SN for PD (P = .03) and hypothalamus for HC individuals (P = .03). The results of voxelwise analysis from statistical parametric mapping for discriminating 3 different PD Averaged [
18 F]9-fluoropropyl-(+)-dihydrotetrabenazine specific uptake ratio 2-dimensional images of healthy control participants (A) and patients with mild PD (C), moderate PD (E), and advanced PD (G). Symmetric and bilateral vesicular monoamine transporter type 2 (VMAT2) binding in dopamine innervation is illustrated in healthy control participants. Asymmetric pattern of nigrostriatal VMAT2 uptake loss is visible in mild PD, while less obvious in moderate PD, and asymmetry almost disappears, but with severe VMAT2 binding decline, in advanced PD. Posterior-to-anterior 3-dimensional views of VMAT2 binding images of dopamine innervation are illustrated for healthy control participants (B), mild PD (D), moderate PD (F), and advanced PD (H). The frame wire in 3-dimensional images indicates the complete volumes of interest of the caudate nuclei, putamen, substantia nigra, and midbrain.
groups from the HC group are shown in eAppendices 1 and 2 and the eFigure in Supplement.
The correlations between nigrostriatal SURs and clinical characteristics of patients with PD were calculated by an exponential regression model as shown in eAppendices 1 and 2 and eTable 1 in Supplement. Figures 2 and 3 illustrate the scatterplots and fitted exponential curves of SURs against disease stage, duration, and clinical scores in the bilateral PPu.
36,37
The SURs of the bilateral striatum exhibited significant correlations to mH-Y stage; disease duration; and UPDRS III, PI/ GD, akinesia, rigidity, and tremor scores, while the SUR in the SN displayed significant correlation only to stage, disease duration, UPDRS III, and PI/GD scores (eAppendix 2 and eTable 1 in Supplement). No statistically significant correlation between quantitative values and clinical characteristics in the hippocampus, amygdala, and raphe was observed. The SURs in the ipsilateral PPu were obviously higher than those of the contralateral PPu as shown in Figure 2 . As the disease progressed to the moderate and to the advanced stages (mH-Y ≥3), the uptake in the bilateral PPu became similar. In addition, SURs in bilateral nigrostriatal regions were exponentially correlated with disease stages with a statistical significance of P < .05 as shown in eTable 1 in Supplement and that indicated 2 phase declines: rapid decline (mild stage) and slower decline (moderate and advanced stages).
Discussion
The present study provided the 2-D and 3-D imaging of VMAT2 distributions in the dopaminergic, serotoninergic, and norepinephrinergic pathways using 18 F-DTBZ PET for HC individuals and patients with mild, moderate, and advanced stages of PD. The correlation between clinical severity and the quantitative measurement of VMAT2 integrity in PD was further explored.
VMAT2 Imaging Feature of HC and PD Groups
The distribution pattern of VMAT2 could be clearly illustrated for HC individuals and patients with PD by both 2-D and 3-D images of 18 F-DTBZ PET ( Figure 1) . As was similarly reported by Lin et al, 30 high uptakes in the SN, striatum (nigrostriatal pathway), NAc, hippocampus, and amygdala (mesolimbic pathway), as well as the raphe (serotonin system) and Abbreviations: HC, healthy control; PD, Parkinson disease; SUR, specific uptake ratio. a Significantly different from HC, P < .001.
F-DTBZ imaging in patients with PD (Figure 1) , the nigrostriatal binding showed a gradual reduction with the disease progression. Regional integrity of VMAT2 was mostly affected in the PPu among all patients with PD, followed by the APu, caudate, and SN. This result was in line with the postmortem results indicating that the apoptosis of dopaminergic neurons in the lateral ventral tier of the SN projecting to the putamen was most severe. The degeneration of dopaminergic pathways was worse in the dopaminergic axonal terminals of the striatum than that in the cell bodies of the SN.
38,40-42 Previous in vivo PET and postmortem studies had proven that VMAT2/dopamine level in the PPu had 70% to 80% reduction in patients with PD with the initial manifestation of symptoms. 16, 25, 28, [43] [44] [45] We also observed the same tendency of decline in 18 F-DTBZ binding for mild PD (70.0% decline in the bilateral PPu). Moreover, the VMAT2 availability in the striatum showed a significant difference between HC individuals and patients with mild PD (Figure 1 ), indicating that 18 F-DTBZ imaging might be a sensitive tool for early detection of dopaminergic degeneration in PD. Furthermore, the striatal SURs correlated with disease severity. The decline of 18 F-DTBZ binding was highest for advanced PD and lowest for mild PD. These observations are in agreement with postmortem studies, with the greatest decrease of dopaminergic innervations in the PPu for more advanced PD. 39,42,46,47 A similar trend was also found in a previous 11 C-DTBZ study of patients with PD of early and moderate stages. 25 There was no significant difference between SURs in moderate and advanced PD in the contralateral PPu region (Table 2 ). This may be owing to the reduction of radioactivity in this region reaching its lower limit earlier than other striatal regions in patients with moderate to advanced PD. One of the important 18 F-DTBZ imaging features of patients with PD was the asymmetric loss of dopaminergic innervations, with an obvious decline in the contralateral striatum ( Figure 1 ; Table 2 ; eAppendices 1 and 2 and the asymmetry index 7 in eTable 2 in Supplement). These asymmetries were consistent with previous studies using 11 C-DTBZ and 99m Tclabeled tropane derivative.
25,48
The significant deficit of 18 F-DTBZ uptake in patients with PD was mainly located in the nigrostriatum from both regional and voxelwise analysis. In the NAc, significant SUR reduction only appeared in the contralateral side for both moderate and advanced PD. However, there was no significant loss of 18 F-DTBZ uptake among the 3 PD stages in the serotonin and norepinephrine systems including the raphe, hippocampus, and amygdala. These findings were consistent with the literature that the dopaminergic neuron damage in PD primarily starts from nigrostriatal, then mesocortical, pathways and finally affects the mesolimbic system in the advanced stage. 1 A previous 11 C-DTBZ study also reported a similar result, with no statistical difference of the VMAT2 activity between patients with PD and age-matched control participants in the raphe that has major serotonergic innervations. F-DTBZ binding of the SN also exponentially related to the UPDRS scores (except rigidity). These findings suggested that SUR level in the SN can provide supplementary information for evaluating the severity of motor symptoms in patients with PD.
The SURs of 18 F-DTBZ in the PPu, the motor part of nigrostriatal projections, displayed good correlation to disease stage and might be a good marker to represent the motor disability and to monitor the effects of therapy for rescuing nigral dopamine neurons in the early disease stage. As disease progressed, the increase of PI/GD scores was highest, followed by akinesia and rigidity scores (Table 1 ). These findings suggested that axial signs may make the greatest impact on the clinical deterioration of PD. Thus, the high correlation of SURs to clinical measurements in this study displayed potential and important application of 18 F-DTBZ imaging for clinical PD severity evaluations in moderate and severe stages. In addition to the motor functions, nonmotor complications, including cognitive and mood changes, might also play important roles in disease progression of PD. 52 Future work should include correlation of cognitive and mood performances to the VMAT2 distributions using 18 F-DTBZ imaging. The SURs of the raphe, amygdala, hippocampus, and LC exhibited an increasing trend with disease severity (Table 2) . In particular, SURs of the LC in moderate and advanced stages showed significant differences compared with HC individuals. Similar results could also be observed in Figure 1 . One possible reason is that the VMAT2 in these regions were relatively preserved in PD, whereas uptake in the occipital lobe might decrease as disease progressed owing to occipital hypoperfusion in the advanced stage of disease.
53,54 Therefore, using the occipital lobe as a reference region, the SURs in the raphe, amygdala, hippocampus, and LC might be overestimated in the moderate and advanced stages. In PD, the severe reduction of VMAT2 density in the nigrostriatal system makes the effect of occipital hypoperfusion on the quantification of striatal regions too minimal to be neglected. Therefore, we suggest that the quantification of VMAT2 availability in extrastriatal regions should be more cautious when using the occipital lobe as a reference region in diseases with occipital hypoperfusion or atrophy.
Other limitations of the present study were the small sample size in each mH-Y stage and use of cross-sectional data. A large number of patients with PD for every mH-Y stage and longitudinal studies for further validation are warranted.
Conclusions
In PD, 18 F-DTBZ PET imaging could potentially provide a stronger power for detecting dysfunction of the dopaminergic system. In addition, SURs of 18 F-DTBZ reveal good correlation to clinical severity of PD. Thus, 18 F-DTBZ imaging is a potential biomarker for monitoring dopaminergic degeneration and may likely be useful for assessing the disease progression of PD.
